西格列汀联合缬沙坦治疗早期糖尿病肾病的效果

Effect of sitagliptin combined with valsartan on early diabetic nephropathy

目的探讨西格列汀联合缬沙坦治疗早期糖尿病肾病的效果。方法选取2017年3月至2019年3月本科室收治的126例早期糖尿病肾病患者为研究对象,按照随机数表法将其分为对照组与观察组,每组63例。对照组患者采用胰岛素联合缬沙坦治疗,观察组患者采用西格列汀联合缬沙坦治疗,对比两组患者的治疗效果。结果治疗后,两组患者的FBG、2 h PBG、HbA1c、HOMA-β及HOMA-IR较治疗前均明显改善,且观察组优于对照组,差异有统计学意义(P<0.05);治疗后,两组患者的Cys C及m AIb水平较治疗前均明显降低,且观察组低于对照组,差异有统计学意义(P<0.05);观察组患者的不良反应总发生率低于对照组,差异有统计学意义(P<0.05);治疗后,两组患者的A-DQOL各项评分较治疗前均明显降低,且观察组低于对照组,差异有统计学意义(P<0.05)。结论西格列汀联合缬沙坦治疗早期糖尿病肾病效果显著,其可降低患者的血糖水平及不良反应发生率,改善胰岛B细胞功能及肾功能,并提高患者的生活质量水平,值得临床推广。

Objective To explore the effect of sitagliptin combined with valsartan in the treatment of early diabetic nephropathy. Methods A total of 126 patients with early diabetic nephropathy admitted in our department from March 2017 to March 2019 were selected as the research objects. The patients were divided into control group and observation group according to random number table method, with 63 cases in each group. The patients in control group were treated with insulin combined with valsartan, while the patients in observation group were treated with sitagliptin combined with valsartan. The therapeutic effects of the two groups were compared. Results After treatment, the FBG, 2 h PBG, HbA1 c,HOMA-β and HOMA-IR in the two groups significantly improved compared with those before treatment, and those in the observation group were better than the control group, the differences were statistically significant(P<0.05);after treatment,the levels of Cys C and mAIb in the two groups were significantly lower than those before treatment, and those in the observation group were lower than the control group, the differences were statistically significant(P <0.05);the total incidence of adverse reactions in the observation group was lower than that in the control group, and the difference was statistically significant(P<0.05);after treatment, the A-DQOL scores of the two groups were significantly lower than those before treatment, and those of the observation group were lower than the control group, the differences were statistically significant(P <0.05). Conclusion Sitagliptin combined with valsartan has a remarkable effect in the treatment of early diabetic nephropathy. It can reduce the blood sugar level and the incidence of adverse reactions, improve the function of islet B cells, renal function, and the level of the quality of life of patients, which is worthy of clinical promotion.